Geffen, OD, FAAO, director of optometric and refractive services at the Gordon Schanzlin New Vision Institute in La Jolla, CA, who was not involved in the research, explained to MNT
Reddys, Natco, Cipla, and others are also now available at significantly lower prices
[1] [2] Zepbound has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis
All the data analyzed and displayed in the present manuscript are available form the corresponding author upon reasonable request
The statements have not been approved by the European Food Safety Authority or the European Commission
Lancet (London, England), 398 (10295), 143155